{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:27:53Z","timestamp":1781058473243,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jgar.2020.09.024","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T19:06:58Z","timestamp":1602270418000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Systematic review and meta-analysis of the efficacy and safety of vancomycin combined with \u03b2-lactam antibiotics in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections"],"prefix":"10.1016","volume":"23","author":[{"given":"Chao","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.09.024_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2020.09.024_bib0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bmj.38834.421713.2F","article-title":"Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study","volume":"333","author":"Wyllie","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2020.09.024_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/j.1326-5377.2009.tb02841.x","article-title":"Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand","volume":"191","author":"Turnidge","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.jgar.2020.09.024_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0035","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin\u2013resistant Staphylococcus aureus bacteraemia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","article-title":"Staphylococcus aureusVancomycin for endocarditis in intravenous drug users","volume":"34","author":"Small","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2020.09.024_bib0045","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0050","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/j.1875-9114.1997.tb03788.x","article-title":"Retrospective evaluation of therapies for Staphylococcus aureus endocarditis","volume":"17","author":"Gentry","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"Suppl","key":"10.1016\/j.jgar.2020.09.024_bib0055","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1093\/clinids\/3.Supplement_2.S250","article-title":"Vancomycin therapy for infective endocarditis","volume":"3","author":"Geraci","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0060","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/AAC.00101-07","article-title":"Impact of empirical therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin susceptible Staphylococcus aureus","volume":"51","author":"Lodise Jr","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0065","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of vancomycin in the management of resistant staphylococcal infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0075","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1086\/605572","article-title":"Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"49","author":"Deresinski","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0080","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","article-title":"Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin","volume":"43","author":"Climo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042103","article-title":"Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"7","author":"Leonard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2020.09.024_bib0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.05473-11","article-title":"In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus","volume":"56","author":"Hagihara","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0095","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00157-18","article-title":"Beta-lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA","volume":"62","author":"Tran","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0100","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2014.06.027","article-title":"Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"36","author":"Dilworth","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2020.09.024_bib0105","series-title":"International prospective register of systematic reviews","author":"PROSPERO","year":"2016"},{"key":"10.1016\/j.jgar.2020.09.024_bib0110","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2020.09.024_bib0115","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2014"},{"key":"10.1016\/j.jgar.2020.09.024_bib0120","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Staphylococcus aureusEarly administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant bloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2020.09.024_bib0125","doi-asserted-by":"crossref","first-page":"ofz077","DOI":"10.1093\/ofid\/ofz077","article-title":"Staphylococcus aureusThe impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant bloodstream infections treated with vancomycin","volume":"6","author":"Zasowski","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01554-17","article-title":"Outcomes of vancomycin plus a \u03b2-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteraemia","volume":"62","author":"Truong","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2020.09.024_bib0135","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/ofid\/ofx163.631","article-title":"Combination vancomycin\/cefazolin (VAN\/CFZ) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)","volume":"4","author":"Trinh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteraemia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.024_bib0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteraemia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0150","doi-asserted-by":"crossref","first-page":"406.e1","DOI":"10.1016\/j.cmi.2016.08.026","article-title":"Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia \u2013 a post hoc analysis in 964 prospectively evaluated patients","volume":"23","author":"Rieg","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.09.024_bib0155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijantimicag.2008.04.011","article-title":"Outcome of patients with methicillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan","volume":"32","author":"Liao","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.09.024_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CCM.0000000000002011","article-title":"Impact of source control in patients with severe sepsis and septic shock","volume":"45","author":"Mart\u00ednez","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2020.09.024_bib0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2020.09.024_bib0170","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin\u2013tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.024_bib0175","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteraemia, relapse, or treatment failure in patients with MRSA bacteraemia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2020.09.024_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02211-18","article-title":"Staphylococcus aureus adjuvant \u03b2-lactam therapy combined with vancomycin for methicillin-resistant bacteraemia: does \u03b2-lactam class matter?","volume":"63","author":"Dilworth","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:13Z","timestamp":1761990913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520302575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":36,"alternative-id":["S2213716520302575"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.024","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis of the efficacy and safety of vancomycin combined with \u03b2-lactam antibiotics in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}